Introduction
Ayurveda descried five types of Shwasa Roga (pathological conditions concerned with difficulty in breathing and associated clinical conditions) and among these, Tamaka Shwasa is one. [1, 2] Tamaka Shwasa is a "Swantarta" Vyadhi, that is, independent disease entity and having its own etiology, pathophysiology, and management. It is mentioned as Yapya Vyadhi, that is, a disease of the chronic nature and difficult to cure. [3] Tamaka Shwasa is basically a disorder of Pranavaha Srotas while other Srotas are also vitiated. [4] The parallel disease entity in contemporary poor if asthma develops in younger age. On the management side, chemotherapy is effective in controlling the severity of attacks and prevents the episodes, but, no disease-modifying effect of chemotherapy is present after the treatment is discontinued. [11] Though environmental control measures are important to avoid or eliminate factors that induce or trigger asthma flare-ups; various formulations such as Ashtangavaleha, [12] Vyaghreehareetakee Avaleha, [13] Shireesha Avaleha, etc., are available in Ayurvedic classics to manage the condition. The present study is aimed to compare the efficacy of Ashtangavaleha (AG) and Vyaghreehareetakee Avaleha (VG) on Tamaka Shwasa in children.
Materials and Methods
Children with clinical features of Tamaka Shwasa with the age limit of 2-16 years of either sex were the research population of the study. The subjects were selected as per the selection criteria from Out Door Patient Department of Kaumarbhritya, IPGT and RA, Gujarat Ayurved University, Jamnagar. [15] • Patients on other drug therapy will be included only after completion of the wash out period prescribed. Grouping and posology
Exclusion criteria
The dose of drug administration was calculated based on Sharngadhara Samhita's dose fixation guidelines. [16] The dose was 5-15 g for both groups depending on the age. In 2-4 years of age group, the dose was 3 g while it was 6 g in 5-7 years, 9 g in 8-10 years, 12 g in 11-13 years and 15 g in Above 13 years age group. The drug was advised to administer in two divided doses Pragbhakta (before food) in morning and evening with luke warm water orally. Both the test drugs were procured from Pharmacy, Gujarat Ayurved University, Jamnagar. 
Investigations

Assessment criteria
The assessment was based on the following parameters. • Very troublesome Kasa, does not even allowing to sleep at night 3
Primary parameters
No sleep difficulty of breathlessness whole night 3 II Improvement in pulmonary function tests parameters III Improvement in frequency and severity in daytime asthma symptoms, overnight asthma symptoms (cough, wheezing, trouble breathing, and activity limitation) IV Global Initiative for Asthma (GINA) level of asthma control, [18] Asthma control test (ACT), [19] Asthma control questioner ACQ. [20] Secondary parameters
•
Positive changes in the blood picture • Reduction in Eosinophils count • Improvements in IgE antibody levels in serum.
Both groups were assessed before and after the treatment period.
Assessment of total effect of therapy
The improvement in quality of life (QOL parameters) [21] were considered in all the below mentioned categories for final assessment.
• Improved: 100% relief of signs and symptoms • Markedly improved: Improvement between >75% and 99% • Moderately improved: Improvement between >50% and 75% 
Statistical analysis
Comparative efficacy in group AG and VG was assessed by applying the unpaired Student's t-test.
Observations
Total 74 patients completed the course of treatment. In group Ashtangavaleha (AG), 36 patients while in group Vyaghreehareetakee Avaleha (VG), 38 patients completed the course of treatment.
In general obcservations out of 100, maximum number of patients that is 27% belonged to 5-7 years age group, 71% male, 87% of Hindu religion, 48% were from middle group of socioeconomic status. In chief complaints Shwaskashtata (breathlessness), Kasa (cough) and Peenas was noted in 100% patient. Ghurghurakam (audible breathing) was complained by 90% patients, expectoration was noted in 70% of patients, 64% patients reported disturbed sleep and Urah-Parshwa Peeda (chest pain/chest tightness). Chronicity of Tamaka Shwasa (1-5 years) was noted in 65% of patients, family history of asthma was reported in 69% patients.
Results
Effect on cardinal symptoms of Tamaka Shwasa
The variations in the effects of Ashtangavaleha and Vyaghreehareetakee Avaleha on the symptoms of Tamaka Shwaasa were statistically insignificant except in cough in which the comparator agent showed better result, which was statistically significant [ Table 1 ]. 
Effect on hematological parameters
On hematological parameters, group AG showed an increase of total white blood cells, eosinophil, differences in the effects of trial and control drugs on the on the hematological parameters were statistically insignificant except TRBC. On biomarker, both the groups showed an increase in the serum levels of IgE and it was more in group VG, but comparative difference between group AG and group VG was statistically insignificant [ Table 3 ].
Effect on pulmonary function test
Peak flow meter test
Both PEF and FEV 1 were increased in both groups, and it was more in group AG, but the comparative effect between group AG and group VG were statistically insignificant [ Table 4 ].
Spirometery
An increase was observed in FEV 1 , FVC and PEF parameters in both the groups. Increase in FEV 1 , FVC and PEF observed in group AG is greater than group VG, but the difference found is statistically insignificant. FEV 1 /FVC% was increased in group VG while it was decreased in group AG and comparative difference within the groups was found statistically significant [ Table 5 ].
Effect on quality of life
Quality of life was assessed on general, physical, psychological and environmental health parameters. In the domain of general health, both groups showed highly significant results but group AG (42.4%) showed better results than group VG (39.0%) while difference was statistically insignificant. In the domain of physical health, both groups showed highly significant results but group AG (36.2%) showed better results than group VG (35.10%) while difference was statistically insignificant. In the domain of psychological health, both groups showed highly significant results but group AG (42.7%) showed better results than group VG (38.7%) while difference was statistically insignificant. In the domain of social health, both groups showed highly significant results but group AG (41.8%) showed better results than group VG (36.4%) while difference was statistically insignificant. In the domain of environmental health both groups showed highly significant results but group AG (28.6%) showed better results than group VG (24.68%) while difference was statistically insignificant. All the QoL parameters were increased in both groups and group AG showed better results than group VG. While comparing between the group AG and group VG, difference was statistically insignificant [ Table 6 ].
Overall effect of therapy
When the individualized overall effect of therapy were considered more number of patients in group AG reached moderate improvement zone when compared with group VG. In marked improvement zone, group AG had more number of patients while in mild improvement zone, group VG had more number of patients [ Table 7 ]. In group AG, overall improvement was 66.66% whereas in group VG, it was 63.15%. While comparing between group AG and VG, the differences was statistically insignificant [ Table 8 ].
Discussion
On Shwasakashtata (breathlessness), frequency of Shwasa Vega, Ghurghurakam (wheezing), Parshvashoola (chest pain/tightness), Kaphanishtheevana (expectoration of thick phlegm), Shleshma Vimokshante Muhurtam Labhate Shukham (getting relief after expectoration of thick phlegm), Peenasa (coryza), Na Chaapi Nidraam Labhate (night symptoms), Kanthodhvamsa (irritation in throat) and Krichchhrabhashita (difficulty in speaking) both intervention agent Ashtangavaleha and the comparator agent Vyaghreehareetakee Avaleha showed better results but while comparing between the groups, the difference was insignificant. Thus, changes made were similar in both the groups. In both the groups, Kasa (coughing) was decreased Vyaghreehareetakee Avaleha showed better results. The ingredients of Vyaghreehareetakee Avaleha act as local counter irritants and block the efferent fibers of the vagus which carry the cough stimuli to the cough center. [22] On the comparison between the groups, the difference was significant (<0.01). Thus, Vyaghreehareetakee Avaleha was found more effective in reducing Kasa than Ashtangaavaleha.
Ashtangavaleha showed promising effect than Vyaghreeharetakee Avaleha on ACT score. On ACQ assessments, Ashtangavaleha showed better results on awakening in night, awakening at morning due to asthma, limitation of activities, shortness of breathing, wheeze, need of bronchodilator, in comparison to Vyaghreehareetakee Avaleha. On total ACQ, changes made by both groups were statistically highly significant but on comparison between groups, the changes made by both formulations were similar and statistically insignificant by P > 0.05. Thus, both formulations have a similar effect on total ACQ. The ingredients of both Ashtangavaleha and Vyaghreehareetakee Avaleha have immunomodulatory activity, which helps in regulating the allergic responses. [23] Immunostimulatory activity of aqueous extract of Kantakari fruits on mice gives strong evidence that the plant is an immunostimulating agent. [24] On hematological parameters, decrease in absolute eosinophil count (AEC) shows a decrease in the magnitude of allergy. Here comparator agent showed better efficacy, so it may be inferred that it is more effective in allergic conditions, but the difference is statistically insignificant. Decrease in erythrocyte sedimentation rate simultaneous decrease in AEC clearly indicates the drugs action on allergic conditions. In group AG and the change was statistically highly significant by P < 0.001. Similarly in group VG, there was 13.04% increase in PEF and 22.49% in FEV 1 and change was statistically highly significant by P < 0.001. On the comparison between the groups, difference was statistically insignificant showed similar effect by both formulations. Thus, both formulations were equally effective on peak flow meter measurements and helpful in managing the severity.
On Spirometry, in group AG and changes were statistically insignificant while, in group VG, changes observed were statistically significant (P < 0.05). Comparative changes between group AG and group VG on FEV 1 and PEF were statistically insignificant. Thus, both formulations have similar effect. A reduced ratio of FEV 1 /forced vital capacity (FVC) indicates obstruction to the flow of air from the lungs. In present trial, FEV 1 /FVC% was increased in group VG. Thus, Vyaghreehareetakee showed superiority over Ashtangavaleha on this parameter.
Quality of life is a key health indicator that should be routinely assessed. For children, it is important to obtain data on disorders that have an impact on the child and place a burden on the family. The QoL was assessed on general, physical, psychological, social and environmental health parameters. In the domain of all the parameters, both groups showed highly significant results but group AG showed better results than group VG while difference was statistically insignificant. In this study, both agents were highly effective in improving QoL. The formulations were having qualities to increases the Bala (strength) which is usually decreased in this condition thus improving the QoL of the child. Due to bio availability enhancer and immunomodulatory activity, the formulations have therapeutic potential for the prevention of allergic diseases. Due to effort made by researcher to educate patient and parents about preservation of the environment, healthy life-style and about exposure to risk factors (concept of Nidana Parivarjana), all the parameters of QoL improved significantly in both groups. Thus, all the QoL parameters assessed were improved significantly in both groups, and group AG showed better results than group VG. While comparing between the group AG and VG, difference was statistically insignificant. These profiles indicate that Tamaka Shwasa significantly reduces the QoL in the patients. The investigator concluded that patients with bronchial asthma express overall lower levels of QoL.
When the individualized overall effect of therapy was considered, more number of patients in group AG reached moderate improvement zone when compared with group VG. In marked improvement zone, group AG had more number of patients while in mild improvement zone group VG had more number of patients. No patient had complete relief in any group. In no improvement zone both the groups are at par. 
Conclusion
Above findings inferred that the test drug Ashtangavaleha is marginally more effective in comparison to Vyaghreehareetakee Avaleha in the management of Tamaka Shwasa in children even though the superiority was statistically insignificant (>0.05).
